U.S. pharma giant copyright scrapped two experimental weight loss pills last year—a the moment-each day capsule, lotiglipron, as a consequence of elevated liver enzymes and a two times-day-to-day tablet, danuglipron, as a consequence of strong Unintended effects—but CEO Albert Bourla has stated the company is set to “Perform and acquire” in